Dr. Hamedifar initiated and led the project to develop the first full-cycle biosimilar candidate in the region back in 2002, a co-development project between Fraunhofer Institute and CinnaGen, the successful outcome of this project paved the way to establish the advanced biopharmaceutical infrastructure in the region. Since then, CinnaGen has become a major player in biopharmaceutical era, focusing on large scale manufacturing of biosimilars with world-class quality. CinnaGen provides life-saving treatments through a diverse range of products for conditions such as multiple sclerosis (MS), cancer, respiratory illnesses, and various rare diseases.